Quadruplet Therapy with Isatuximab for Newly Diagnosed Multiple Myeloma

Combining bortezomib, lenalidomide, and dexamethasone (VRd) is a well-established frontline therapy for treating multiple myeloma. Investigators now report a long-term follow-up of a phase 3, industry-sponsored, multicenter trial that randomized 446 transplant-ineligible patients with multiple myeloma to VRd plus isatuximab (isa-VRd) or VRd alone.

Patients (age range, 18–80) had previously untreated disease and were ineligible for transplantation due to age over 65 or significant comorbidities. Four 6-week induction cycles in each study arm were followed by continuous 4-week maintenance cycles of isa-Rd or Rd. For 25 patients receiving Rd whose disease progressed, crossover to isa-Rd was permitted. The median follow-up was 59.7 months.

The 60…